ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
신경조절 기기 시장 규모는 2023년에 57억 1,000만 달러에 달했습니다. 이 시장은 2024-2030년의 예측 기간 중 8.95%의 CAGR로 확대하며, 2030년에는 95억 6,000만 달러에 달할 것으로 예측됩니다. 신경조절 기기의 수요는 주로 신경질환의 유병률 증가와 만성 통증으로 고통받는 환자 증가에 의해 주도되고 있습니다. 또한 연구개발의 활성화와 주요 기업간의 제휴가 시장 성장에 크게 기여하고 있습니다. 고령화 사회의 진전은 노인들이 신경질환과 만성통증에 걸리기 쉽기 때문에 이러한 수요를 더욱 증가시키고 있습니다. 이러한 요인들이 복합적으로 작용하여 2024-2030년의 예측 기간 중 신경조절 기기 시장은 긍정적인 성장을 보일 것으로 예상됩니다.
신경질환의 유병률 증가는 신경조절 장비의 광범위한 적용으로 인해 시장을 크게 견인할 것으로 예상됩니다. 세계보건기구(WHO)가 2024년 3월에 제공한 데이터에 따르면 편두통 및 기타 두통 장애는 2021년 전 세계 31억 명에게 영향을 미쳤습니다.
파킨슨 재단이 2022년 발표한 자료에 따르면 미국에서는 매년 약 9만 명이 파킨슨병(PD) 진단을 받고 있으며, 2030년에는 120만 명에 달할 것으로 예측되고 있습니다. 신경질환의 유병률이 계속 증가함에 따라 신경조절 장비에 대한 수요가 증가하여 시장 성장을 더욱 촉진할 것으로 예상됩니다.
세계의 신경조절 기기 시장에 대해 조사했으며, 시장의 개요와 유형별, 제품별, 용도별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.
목차
제1장 신경조절 기기 시장 보고서 서론
제2장 신경조절 기기 시장의 개요
제3장 경쟁 구도
제4장 규제 분석
미국
유럽
일본
중국
제5장 신경조절 기기 시장의 주요 요인 분석
신경조절 기기 시장 성장 촉진요인
신경조절 기기 시장 성장 억제요인과 과제
신경조절 기기 시장 기회
제6장 신경조절 기기 시장의 Porter's Five Forces 분석
제7장 신경조절 기기 시장 평가
유형별
제품별
용도별
최종사용자별
지역별
제8장 신경조절 기기 시장의 기업과 제품 개요
Medtronic
Abbott Laboratories
Boston Scientific Corporation
LivaNova PLC
NeuroSigma, Inc.
NEVRO CORP.
Synapse Biomedical Inc.
NeuroPace, Inc.
Bioventus
Soterix Medical Inc.
Neuronetics Inc.
ALEVA NEUROTHERAPEUTICS
Magstim
SPR Therapeutics, Inc.
Theranica Bio-Electronics Ltd.
electroCore, Inc.
Neuros Medical
Magnus Medical, Inc.
Integer Holdings Corporation
Mainstay Medical
제9장 KOL의 견해
제10장 프로젝트 어프로치
제11장 DelveInsight 소개
제12장 면책사항과 문의
KSA
영문 목차
영문목차
Neuromodulation Devices Market by Type (Invasive and Non-Invasive), Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and Others), Application (Pain Management, Neurological Disorder, Respiratory Disorders, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a static CAGR forecast till 2030 owing to growing prevalence of neurological disorders and rise in numbers of patients suffering from chronic pain.
The neuromodulation devices market was valued at USD 5.71 billion in 2023, growing at a CAGR of 8.95% during the forecast period from 2024 to 2030 to reach USD 9.56 billion by 2030. The demand for neuromodulation devices is primarily driven by the growing prevalence of neurological disorders and the increasing number of patients suffering from chronic pain. Additionally, increasing research and development activities, along with collaborations among key players, are significantly contributing to market growth. The rising aging population further compounds this demand, as older adults are more susceptible to neurological conditions and chronic pain. These factors collectively position the neuromodulation devices market for positive growth during the forecast period from 2024 to 2030.
Neuromodulation Devices Market Dynamics:
The growing prevalence of neurological disorders is anticipated to significantly propel the market, driven by the widespread application of neuromodulation devices in their treatment. According to data provided by the World Health Organization (WHO) in March 2024, migraine and other headache disorders affected 3.1 billion people globally in 2021.
Data from the Parkinson's Foundation in 2022 indicates that approximately 90,000 individuals are diagnosed with Parkinson's disease (PD) each year in the United States, with projections suggesting that the number of affected individuals will reach 1.2 million by 2030. As the prevalence of neurological conditions continues to rise, the demand for neuromodulation devices is expected to increase, further driving market growth.
Additionally, data from the WHO in June 2023 revealed that around 619 million people were living with lower back pain (LBP) in 2020, with projections indicating that this number is expected to rise to approximately 843 million cases by 2050 worldwide. This increase in LBP cases is primarily attributed to population growth and an aging demographic. Restorative neurostimulation devices are designed to trigger repeated contractions of the multifidus muscles, effectively restoring their strength and stabilizing the spine. As the prevalence of chronic pain continues to rise, the demand for neuromodulation devices is expected to increase, significantly propelling market growth.
Key players in the industry are increasingly focusing on research and development to create innovative neuromodulation systems, further enhancing market growth. For instance, in April 2024, Magnus Medical, Inc., a company specializing in therapeutic neuromodulation, launched the SAINT neuromodulation system specifically designed for treating major depressive disorders. This system utilizes structural and functional magnetic resonance imaging (MRI) scans to guide a proprietary algorithm that accurately identifies the precise anatomical targets for neurostimulation in individuals with major depression. By optimizing treatment effectiveness through targeted stimulation, this innovative approach aims to improve patient outcomes and enhance the overall efficacy of depression therapies. Such advancements are expected to significantly enhance patient outcomes and further drive market growth.
However, certain factors, such as the high cost of these devices and the risk of device-associated complications, may constrain the growth of the neuromodulation devices market.
Neuromodulation Devices Market Segment Analysis:
Neuromodulation Devices Market by Type (Invasive and Non-Invasive), Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and Others), Application (Pain Management, Neurological Disorder, Respiratory Disorders, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product segment of the neuromodulation devices market, spinal cord stimulators are expected to hold a significant market share during the forecast period. This is attributed to the growing patient population suffering from chronic pain, failed back syndrome, lower back pain, and complex regional pain syndrome (CRPS). According to data from the Centers for Disease Control and Prevention (CDC) in April 2023, it was estimated that 20.9% of adults, accounting for approximately 51.6 million individuals, were suffering from chronic pain. Of these, 6.9%, or about 17.1 million people, experienced high-impact chronic pain in 2021 in the United States, which significantly restricted their daily activities. Spinal cord stimulation devices are effective in treating various types of chronic pain, thereby driving segment growth and contributing to the overall expansion of the neuromodulation devices market.
Recent advancements in spinal cord stimulators, such as rechargeable batteries and wireless remote technology, are also contributing to segment growth. For instance, in December 2022, Abbott Laboratories launched the Eterna(TM) spinal cord stimulation (SCS) system for the treatment of chronic pain. The Eterna SCS system incorporates Abbott's proprietary BurstDR stimulation, which mimics the natural firing patterns found in the brain, providing superior pain relief. This neuromodulation device offers an optimized experience by allowing wireless charging as infrequently as five times per year. Such developments by key players are expected to drive market growth.
Overall, these factors are likely to fuel segment growth and foster the expansion of the neuromodulation devices market during the forecast period.
North America is expected to dominate the overall neuromodulation devices market:
North America is expected to dominate the overall neuromodulation devices market during the forecast period. This dominance can be attributed to the rising number of patients suffering from neurological disorders and increasing product development activities by key players. Additionally, the growing geriatric population is a significant factor contributing to the growth of the neuromodulation devices market in this region.
According to data provided by the Centers for Disease Control and Prevention (CDC) in April 2023, an estimated 6.7 million people aged 65 years or older were living with Alzheimer's disease, with projections indicating this number could nearly triple, reaching 14 million by 2060 in the United States. The rising prevalence of various neurological disorders is likely to be a key driver for the growth of the neuromodulation devices market in North America.
Further supporting this trend, the CDC reported in May 2024 that approximately 3 million people were suffering from epilepsy in the United States in 2021. Such active cases encourage key players to develop neuromodulation devices specifically for epilepsy treatment. For example, in March 2021, NeuroPace, Inc. announced that it received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for its RNS(R) System, which is designed to treat idiopathic generalized epilepsy. The RNS System is a brain-responsive neuromodulation system that delivers personalized, targeted treatment directly at the seizure source and serves as adjunctive therapy for adults suffering from drug-resistant focal epilepsy. These factors are likely to drive significant growth in the neuromodulation devices market in North America.
Moreover, the Asia-Pacific region is poised for future growth in the neuromodulation devices market. This potential is driven by improving healthcare infrastructure, increasing per capita healthcare expenditure, rising disposable income, and a growing elderly population. Additionally, recent product development activities among key manufacturers aiming to expand their product portfolios in the APAC region will also boost the market. For instance, in 2021, Neurolief Ltd., a neurotechnology innovator, entered into an exclusive agreement with Sawai Pharmaceutical Co., Ltd. to develop and market Relivion(R), a non-invasive brain neuromodulation device for migraine and depression in Japan. This device is designed for placement around the head, delivering targeted stimulation to the occipital and trigeminal nerves. This targeted stimulation generates a cumulative effect by releasing neurotransmitters in the brainstem, modulating brain networks, and ultimately aiding in pain management.
Neuromodulation Devices Market Key Players:
Some of the key market players operating in the neuromodulation devices market include Medtronic, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus, Soterix Medical Inc., Neuronetics Inc., ALEVA NEUROTHERAPEUTICS, Magstim, SPR Therapeutics, Inc., Theranica Bio-Electronics Ltd., electroCore, Inc., Neuros Medical, Magnus Medical, Inc., Integer Holdings Corporation, Mainstay Medical, and others.
Recent Developmental Activities in the Neuromodulation Devices Market:
In January 2024, Boston Scientific Corporation announced that it had entered into a definitive agreement to acquire Axonics, Inc. for an amount of USD 3.4 billion. Through this acquisition, Boston Scientific expanded its neurostimulation device product portfolio with advanced technology development in sacral neuromodulation.
In March 2022, Bioventus announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance to the next-generation StimRouter(R) Neuromodulation System for the treatment of chronic pain. StimRouter is a minimally invasive neuromodulation medical device comprising a thin implanted lead with a conductive electrode, an external electric field conductor (E-EFC), and the StimRouter Plus Mobile Application.
In March 2021, Helius Medical received the US FDA approval for Portable Neuromodulation Stimulator approval for short-term treatment of gait deficit due to multiple sclerosis.
In January 2021, Boston Scientific Corporation received FDA approval for its fourth-generation Vercise Genus Deep Brain Stimulation (DBS) System used to treat symptoms in patients with advanced Parkinson's disease.
Key Takeaways from the Neuromodulation Devices Market Report Study
Market size analysis for current Neuromodulation Devices Market size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
Key companies dominating the Neuromodulation Devices market.
Various opportunities available for the other competitors in the Neuromodulation Devices Market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current Neuromodulation Devices market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Neuromodulation Devices market growth in the coming future?
Target Audience who can be benefited from this Neuromodulation Devices Market Report Study
Neuromodulation Devices product providers
Research organizations and consulting companies
Neuromodulation Devices related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in Neuromodulation Devices
Various end-users who want to know more about the Neuromodulation Devices Market and the latest technological developments in the Neuromodulation Devices Market.
Frequently Asked Questions for the Neuromodulation Devices Market:
1. What are Neuromodulation Devices?
Neuromodulation devices, also known as neurostimulation devices involve the application of electrodes to the brain, the spinal cord, or peripheral nerves. These devices can increase or decrease the activity of the nervous system by generating necessary electrical stimulation.
2. What is the market for Neuromodulation Devices?
The neuromodulation devices market was valued at USD 5.71 billion in 2023, growing at a CAGR of 8.95% during the forecast period from 2024 to 2030 to reach USD 9.56 billion by 2030.
3. What are the drivers for the Neuromodulation Devices market?
The neuromodulation devices market is slated to witness prosperity owing to factors such as the growing prevalence of neurological disorders and the rise in the number of patients suffering from chronic pain. Increasing R&D activities and collaboration among key players and the rising aging population are the key factors that are responsible for contributing to the positive growth of the neuromodulation devices market during the forecast period from 2024 to 2030.
4. Who are the key players operating in the Neuromodulation Devices market?
Some of the key market players operating in the neuromodulation devices market include Medtronic, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus, Soterix Medical Inc., Neuronetics Inc., ALEVA NEUROTHERAPEUTICS, Magstim, SPR Therapeutics, Inc., Theranica Bio-Electronics Ltd., electroCore, Inc., Neuros Medical, Magnus Medical, Inc., Integer Holdings Corporation, Mainstay Medical, and others.
5. Which region has the highest share in the Neuromodulation Devices market?
North America is expected to dominate the overall neuromodulation devices market during the forecast period from 2024 to 2030. This domination is due to the rise in several patients suffering from neurological disorders and increasing product development activities by key players. Additionally, the growing geriatric population is another key factor contributing to the growth of the neuromodulation devices market in this region.
